Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs
Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of ...
Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of ...
Astellas Pharma’s path to winning the first drug approval for a particular promising gastrointestinal cancer target has hit a detour. ...
Loewen Cavill, co-founder and CEO of Amira, never expected to work in the menopause space. But then her aunt was ...
Last week, FDA authorized the State of Florida to import pharmaceuticals from Canada. The price ...
The legal status of marijuana in the United States is comparable to the Korean War: The conflict ceased long ago, ...
Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is ...
When the Covid-19 pandemic hit, contract development and manufacturing organizations (CDMOs) became indispensable partners to the biopharmaceutical companies that developed ...
Imagine being a parent to a 20-month-old and learning through a developmental screening that your toddler might have autism spectrum ...
Goldman Sachs Asset Management has expanded to biotech investments in recent years. The investment firm is now preparing to ramp ...
Clinical trial attrition can be detrimental to clinical outcomes, patient well-being and the financial health of research programs. Clinical trial ...
Copyright © 2024 The Israel Chronicle News.
The Israel Chronicle News is not responsible for the content of external sites.